

VPA10794/001/001

Uniferon 20 % w/v Solution for Injection

Variation	Summary	Date
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - - Vet - G.I.15 z) - Changes to the labelling or the package leaflet which are not connected with the summary of product characteristics - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	04/08/26
Vet - G.I.12	VRA-S - Vet - G.I.12 - - Vet - G.I.12 - Changes to the withdrawal period for a veterinary medicinal product	08/06/26
Vet - G.I.4	VRA-S - Vet - G.I.4 - - Vet - G.I.4 - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data.	08/06/26
Vet - G.I.3 b)	VRA-R - Vet - G.I.3 b) - - Vet - G.I.3 b) - Change(s) in the SPC, labelling or package leaflet intended to implement the outcome of a procedure or recommendations from the competent authority or the Agency concerning risk management measures in pharmacovigilance related to veterinary medicinal products - Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon	08/06/26
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	08/06/26
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	11/12/24
Vet - F.II.e.6 z)	VRA-R - Vet - F.II.e.6 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.e.6 z) Quality Changes - Container closure system - Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used)) - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	08/08/24

Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	15/05/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	19/09/23
Vet - B12 c)	VNRA - Vet - B12 c) - c) Minor changes to an approved test procedure for an in-process test - B12 c) Changes to the quality part of the dossier: Minor changes — to an approved test procedure for an in-process test — for active substance; — for the finished product	09/05/23
Vet - B12 f)	VNRA - Vet - B12 f) - f) Minor changes to an in-process limit range for the finished product - B12 f) Changes to the quality part of the dossier: Minor changes — to an in-process limit range for the finished product	09/05/23
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	09/05/23
Vet - F.II.b.1 z)	VRA-R - Vet - F.II.b.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.1 z) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	30/03/23
Vet - C10 a)	VNRA - Vet - C10 a) - a) Administrative information concerning the holder's representative - C10 a) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — administrative information concerning the holder's representative	15/09/22
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	01/07/22
B.II.e.6.b	IA - B.II.e.6.b - b) Change that does not affect the product information - B.II.e.6.b - QUALITY CHANGES - FINISHED PRODUCT - Container closure system - Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic	07/02/22

	used)) - Change that does not affect the product information	
--	--	--